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Summary
Intestinal transplantation (ITx) has evolved from an experimental procedure
toward a clinical reality but remains a challenging procedure. The aim of this sur-
vey was to analyze the multicenter Belgian ITx experience. From 1999 to 2014, 24
ITx in 23 patients were performed in Belgium, divided over five centers. Median
recipient age was 38 years (8 months–57 years); male/female ratio was 13/10; six
were children; and 17 adults. Intestinal failure was related to intestinal ischemia
(n = 5), volvulus (n = 5), splanchnic thrombosis (n = 4), Crohn (n = 2),
pseudo-obstruction (n = 2), microvillus inclusion (n = 2), Churg-Strauss
(n = 1), necrotizing enterocolitis (n = 1), intestinal atresia (n = 1), and chronic
rejection (n = 1). Graft type was isolated ITx (n = 9), combined liver-ITx
(n = 11) and multivisceralTx (n = 4). One was a living donor-related transplan-
tation and five patients received simultaneously a kidney graft. Early acute rejec-
tion occurred in 8; late acute rejection in 4; and chronic rejection in 2. Two
patients developed a post-transplant lymphoproliferative disease. Nine patients
have died. Among 14 survivors at last follow-up, 11 have been transplanted for
more than 1 year. None of the latter has developed renal failure, and all were
nutritionally independent with a Karnofsky score > 90%. One-/five-year patient
and graft survivals were 71.1%, 62.8%, 58.7% and 53.1%, respectively. Based on
this experience, ITx has come of age in Belgium as a lifesaving and potentially
quality of life restoring therapy.
Introduction
Over the last two decades, intestinal transplantation (ITx)
has evolved from an experimental procedure toward a
valuable and lifesaving treatment for patients suffering
from intestinal failure (IF) and invalidating complications
of total parenteral nutrition (TPN) [1,2]. However, ITx
still remains a challenging surgical, medical, and immuno-
logical procedure whose long-term results remain inferior
to those obtained in other solid abdominal organ trans-
plantations. This is due to the strong organ immunogenic-
ity and the subsequent need for profound and chronic
immunosuppression (IS) with its associated side effects
[1,3]. The decision to transplant these patients has there-
fore to be taken carefully, and ITx has been relatively
rarely applied in Belgium compared to certain North
American centers [2,4,5]. To increase the donor pool and
optimize organ exchange, Belgium actively participates in
the Eurotransplant (ET) organization which is a collabora-
tive framework of 8 European countries [6].
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The Belgian experience has been collected based on a ret-
rospective survey organized by the Belgian Liver and Intes-
tine Advisory Committee (Be-LIAC). Patient-specific data
forms of the Intestinal Transplant Registry (ITR) and an
additional questionnaire-based survey were gathered until
May 31st, 2014 [7]. The data collection comprised overall
activity, recipient and donor characteristics, blood group
(ABO) compatibility, donor–recipient human leukocyte
antigen (HLA) A-/B-/DR-mismatches, panel reactive anti-
bodies (PRA), cross-match, waiting time, graft type, ische-
mia time, surgical technique, immunosuppressive
regimen, intensive care unit (ICU) and hospital stay, rejec-
tion, post-transplant lymphoproliferative disease (PTLD),
renal function, and finally 1-/5-year patient and graft sur-
vival rates. The renal function was analyzed pretransplant,
and at 1-/3-/5-year post-transplant by the estimated glo-
merular filtration rate (eGFR) which was calculated
according to the formula for adults adapted from Levey:
186*(serum creatinine!1.154)*(age!0.203)*1.212 (if patient
is black)*0.742 (if female) [8]. For children, the adapted
Schwartz formula was used: 0.413*(height/serum creati-
nine) [9].
At last follow-up, a cross-sectional analysis of TPN inde-
pendence, weight evolution, and Karnofsky score (clinical
scoring for performance status from the physician’s per-
spective) of the patients who were transplanted for more
than 1 year was performed. Data were collected by two
researchers (LC, JP), entered and tabulated using Excel
(Microsoft Office 2013), and exported to Graphpad Prism
5 (GraphPad Software Inc., La Jolla, CA, USA). Results are
reported as median (range) and survival curves were deter-
mined following Kaplan–Meier.
Results
Response rate to Belgian survey
Five of seven Belgian transplantation centers performed at
least one ITx and all completed the survey.
Activity
Between March 1999 and June 2014, 24 ITx were per-
formed in 23 patients: 15 ITx were performed at the Uni-
versity Hospitals Leuven, 5 (of them 1 re-Tx) at the
University Hospital of Li!ege, 2 at the University Hospital of
Ghent, 1—which was the first in Belgium—at the Univer-
sity Hospital of Saint-Luc in Brussels, and 1 at the Univer-
sity Hospital of Antwerp.
Data abstraction is reported in detail in Table 1.
Recipient demographics, indications, waiting time
Age of the 23 patients at the time of their first transplant
was 37 years 5 months (8 months–56 years 8 months).
The male/female ratio was 13/10. Six patients (26%) were
pediatric (< 18 years) and 17 (74%) were adult. Preopera-
tive body mass index (BMI) was 19.3 kg/m2 (10.9–
39.3 kg/m2). All patients suffered from IF and associated
life-threatening complications such as repetitive infection,
venous access problems, or liver failure. IF was a conse-
quence of anatomical or functional short bowel syndrome
due to intestinal ischemia (n = 5), volvulus (n = 5), dif-
fuse splanchnic thrombosis (n = 4), Crohn’s disease
(n = 2), chronic intestinal pseudo-obstruction (n = 2),
microvillus inclusion disease (n = 2), Churg-Strauss vas-
culitis (n = 1), necrotizing enterocolitis (n = 1), intestinal
atresia (n = 1), and chronic rejection of the first allograft
(n = 1). The latter patient, a 9-year-old boy, was the only
patient who was re-transplanted, 6 years after removal of
the first graft. PRA was negative in all, apart in the latter
(100%) and the first ITx in this cohort (40%). At time of
ITx, 11 patients (45.8%) were in hospital and 13 (54.2%)
at home. Time on the waiting list was 5 months (2 days–
2 years 8 months).
Donor demographics
Deceased donors
The cause of death of the 23 deceased donors was an iso-
lated head trauma (n = 11; 48%), intracranial bleeding
(n = 6; 26%), anoxia (n = 3; 13%), suicide (n = 2; 9%),
and CO intoxication (n = 1; 4%). Donor age was 16 years
(3 months–38 years). Sixteen donors (70%) were male and
7 (30%) female. Their body mass index was 17.9 kg/m2
(11.4–27.7 kg/m2). Stay on the ICU prior to procurement
was 2.5 days (1–9 days). The donor/recipient weight ratio
was 0.91 (0.4–1.5).
Living donor
A 34-year-old female (blood group: O+; weight: 44 kg;
height: 168 cm) received an intestinal allograft from her
59-year-old mother (blood group: O+; weight: 50 kg;
height: 160 cm). This donor/recipient weight ratio was 1.14
[10].
In the donor, no signs of malabsorption and/or steatho-
rea were observed postdonation. She had obstipation pre-
operatively which disappeared postoperatively and evolved
in a normal bowel movement pattern. Interestingly, daily
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statin intake could be stopped due to a drop in cholesterol
levels after donation.
ABO compatibility, HLA-mismatches, and cross-match
ABO blood group was compatible in 10 transplants (42%)
and identical in 14 (58%). As there was no attempt at HLA
matching between donors and recipients at the moment of
transplantation, this resulted in a mean donor–recipient
HLA A-/B-/DR-mismatch of 1/2/1. No difference was
found between those who died (mean HLA mismatch: 1/2/
1) and those who survived (mean HLA mismatch: 1/2/1).
Cross-matches were negative in all, apart from the retrans-
plant case.
Type of graft and surgical technique
Three different types of grafts were transplanted (Fig. 1,
Panel a–c). An isolated small bowel was transplanted in
nine patients (37.5%)—of whom 2 received an additional
kidney for secondary enteric hyperoxaluria as previously
reported [11]—; 11 patients (46%) underwent a combined
liver and ITx (cLi-ITx)—of whom 3 received an additional
colon and 2 an additional kidney—; and 4 patients
(16.5%) had a multivisceral Tx (MvTx) of whom 2
received an additional colon and 1 a simultaneous kidney
transplant. All 11 cLi-ITx were performed according the
Omaha technique as described by Sudan et al. [12]. Inter-
estingly, apart from the first 4 cLi-ITx performed in Brus-
sels and Leuven (before 2005) in whom the tail of the
pancreas graft was stapled before implantation, all other
transplanted liver-intestinal grafts (n = 7) included a full
pancreas as was the case in the 4 MvTx, according to the
technique described by Tzakis et al. [13]. In the latter
patients, splanchnic exenteration was followed by en-bloc
transplantation of stomach, duodenum, pancreas, and
small bowel. Three of them underwent embolization of
the superior mesenteric artery and celiac trunk prior to
splanchnic exenteration in order to minimize blood loss
[14]. From the living donor, one-third (200 cm) of the
distal small bowel was procured and transplanted accord-
ing to the technique described by Gruessner et al. [15]—
paying attention to leave 25 cm of donor distal ileum
intact for vitamin B12 resorption. Overall, cold ischemia
time was 5 h 20 min (2 h 19 min–9 h 31 min) and warm
ischemia time was 32 min (22–75 min). Primary closure
of the abdomen could be achieved in 22 procedures
(91.7%). In 2 cases (8.3%) additional mesh repair was
required. Two patients, of whom the first was the living-
related ITx and the second a 9-year-old girl, received sub-
cutaneous self-inflatable tissue expanders pretransplant to
create additional skin and facilitate abdominal closure. In
both, the abdomen could be closed after transplantation
without difficulties.
Immunosuppressive treatment
Induction IS was given to 20 ITx recipients (83.3%), of
which 17 received Basiliximab (anti-IL2) and 3 ATG (Thy-
moglobuline). All patients received tacrolimus-based main-
tenance IS: In triple therapy with azathioprine and steroids
in 16 patients (66.7%); two patients (8.3%) were treated
(a) (b) (c)
Figure 1 Three types of intestinal transplantation were performed in the Belgian experience. Panel a: isolated intestinal transplantation (n = 9;
37.5%), two received an additional kidney Panel b: combined liver and intestinal transplantation (n = 11; 46%) of which four were combined with a
pancreatic head and seven with a full pancreas; three received an additional colon and two an additional kidney Panel c: multivisceral transplantation
(n = 4, 16.5%); two received an additional colon and one an additional kidney.
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with mycophenolate mofetil instead of azathioprine; six
patients (25%) received dual therapy with tacrolimus and
steroids. Two months after transplantation, one patient
(MvTx) received additional therapy with anm-Tor inhibitor
because the histology of the explant specimen revealed a
metastatic pancreatic neuro-endocrine tumor. One year
later, the patient remains disease-free. Another patient who
developed a PTLD was also switched to an m-TOR inhibi-
tor.
In 13 consecutive ITx (54.2%) from the same center
(University Hospitals Leuven)—who received their graft
from a deceased donor—an immunomodulatory protocol
was applied [16,17]. This protocol aims to redirect the allo-
immune response toward the intestinal allograft from a
cytotoxic toward a regulatory response by activation of T-
regulatory cells. The protocol was experimentally proven
and consists in: peri-transplant donor-specific-blood trans-
fusion (DSBT) (activates T-regulatory cells); avoiding high-
dose steroids/calcineurin inhibitors (abrogates DSBT-
effect/inhibits T-regulatory cells); and maneuvers reducing
reperfusion injury (among them glutamine administration
and anti-TNF alpha) and endotoxin translocation (bowel
decontamination).
Post-transplant hospital stay
First post-transplant ICU stay was 9 days (2–31 days), and
post-transplant hospital stay was 3 months (21 days–
2 years).
Rejection
In most cases, diagnosis of rejection was made on biopsy
and treated with high-dose steroids (Solu-Medrol!;
3 * 500 mg–1 g/day), and—if unresponsive—by muromo-
nab-CD3, thymoglobulin or immunoglobulins.
Early biopsy-proven rejection (within the first 3 months
post-Tx) occurred in 8 cases (33.3%). Six of them (75%)
(patients who were not treated with the immunomodula-
tory protocol) lost their graft of whom 5 died and 1 was re-
transplanted; the other two rejections were reversible with
steroids.
Late biopsy-proven acute rejection (after the first
3 months post-Tx) occurred in four of 16 (25%) grafts that
survived longer than 3 months; one should take into
account that five grafts were lost within the first 3 months
and that three patients did not yet reach 3 months survival
at the moment of data collection. One of these four patients
died due to sepsis, in the remaining three patients, rejection
was reversed.
Chronic rejection with subsequent graft loss was seen in
two cases (8.3%). Both patients received an isolated graft
and both endured an acute rejection at respectively
7 months and 1 year 7 months post-Tx. Following trans-
plantectomy, they were considered for MvTx; the first
patient was re-transplanted 6 years later and was doing well
at last follow-up, the second ITx patient (living-related
donation) unfortunately could not be listed for this proce-
dure in Belgium as being a non-ET resident (Poland). She
finally died (without access to re-transplantation) 4 years
after transplantectomy.
Post-transplant lymphoproliferative disease
Two patients (8.7%) developed PTLD. A 5-year-old child
developed severe myelodysplasia 4 years after cLi-ITx. To
limit the disease progression, IS therapy was stopped. Bone
marrow transplantation was refused, and at last follow-up
(3 years 6 months later), the patient was doing well with-
out any IS and a fully functioning graft. The second patient
was a 9-year-old child who developed Epstein–Barr-virus-
induced PTLD after receiving his second ITx. He was trea-
ted with rituximab and solely received an m-Tor inhibitor
as IS. Two years later, at last follow-up, the child was doing
well with a fully functioning graft.
Renal function
Evolution of eGFR is shown in Fig. 2. The median pre-
transplant eGFR was 91 ml/min (except of 3 who were on
dialysis pretransplant). At 1-year (63 ml/min), 3-year
(63 ml/min) and 5-year post-transplant (61 ml/min), the
renal function remained stable and none of the patients
required chronic dialysis post-transplant.
Figure 2 The estimated glomerular filtration rate (eGFR) was analyzed
pretransplant (median: 91 ml/min) (except of three who were on dialy-
sis pretransplant). At 1-year (63 ml/min), 3-year (63 ml/min), and 5-year
post-transplant (61 ml/min), the renal function remained stable and
none of the patients required chronic dialysis post-transplant.
1366 © 2015 Steunstichting ESOT 28 (2015) 1362–1370
Belgian experience with intestinal transplantation Ceulemans et al.
Survival and cause of death
One- and 5-year patient survival rates were 71.1% and
58.7%, respectively (Fig. 3, Panel a). With a median patient
follow-up of 2 years 6 months (20 days–12 years), 14
patients (60.9%) survived, and 9 died (39.1%). Survival of
the patients who died was 4 months (22 days–11 years
10 months). Causes of death were as follows: sepsis (n = 4)
(two bacterial and two Aspergillus related), intracranial
bleeding (n = 1), mycotic aneurysm-related hemodynamic
shock (n = 1), nonsteroidal anti-inflammatory drug
(NSAID)-induced enteropathy (n = 1), complicated IF
after graft loss (n = 1), and unexplained sudden death
(n = 1).
One- and 5-year graft survivals (death uncensored) were
62.8% and 53.1%, respectively (Fig. 3, Panel b). Graft
survival at last follow-up was 1 year 9 months (22 days–
12 years). Of the 14 patients who were alive at last follow-
up, one lost his graft due to chronic rejection and was
re-transplanted. Six (66.7%) of 9 deceased patients died
with a functioning graft whereas 3 (33.3%) had lost their
graft prior to death. The reasons for their graft loss were
early acute rejection (n = 1), late acute rejection (n = 1),
and chronic rejection (n = 1).
The 5-year patient survival rate of the 13 consecutive ITx
recipients—who received their graft from a deceased donor
—and were treated with an immunomodulatory protocol
was 90%, which is higher compared to the other nine
patients who did not receive the protocol and had a sur-
vival of 33% (log rank, P = 0.0055) (Fig. 4).
Cross-sectional analysis at last follow-up of 11 surviving
patients who were transplanted for more than 1 year
Follow-up of the 11 patients was 7 years 2 months (2 years
1 month–12 years). These survivors had a functioning graft
and were TPN—and intravenous fluid—free. This was
reflected by their weight and BMI gain of 12.3 kg and
2.6 kg/m2, respectively. The Karnofsky performance score
was > 90%, reflecting resumption of their normal daily
activities.
Discussion
In contrast to liver or kidney failure, for which solid organ
transplantation is widely accepted as the best treatment
regarding survival and quality of life, TPN still represents
the first line of treatment for end-stage IF [1]. TPN indeed
significantly improves outcome of IF, resulting in a current
1- and 5-year survival rate of 91% and 70% (vs. 77% and
58% for ITx, according to the last era (2000–2013) reported
by the ITR) [18,19]. However, long-term TPN may lead to
life-threatening complications such as liver failure,
impaired venous access or recurrent infections. In these sit-
uations, ITx represents a lifesaving option with—poten-
tially—a benefit of restoring the daily activities, like in the
Belgian cohort where all surviving patients achieved nutri-
tional independence and a high Karnofsky performance
score (> 90%) [2,20].
Apart from very few historical procedures, it was only
with the introduction of tacrolimus by Starzl (University of
Pittsburgh) that short-term results improved and that ITx
became a clinical reality [21]. Following encouraging results
from Pittsburgh in the early nineties interest for ITx rose
worldwide with the first Belgian ITx performed in 1999.
Recently however, the ITR reported a decline in the annual
rate of ITx from 200/year in 2008 till only 100/year in 2012
[7,22]. This might be attributed to an improvement in
TPN and IF-management and vascular access with respec-
tively fewer liver failure and line-related complications
[23,24].
The same decline is seen within ET where the highest
annual rate of ITx was recorded in 2008, when 16 patients
received an intestinal graft (Fig. 5). From then, a steadily
decrease with only 5 ITx procedures in 2013, has been
observed [6]. From the first ITx in 1987 until May 31,
2014, 160 ITx were performed within four ET countries
(Germany, Austria, the Netherlands, and Belgium), divided
over 17 transplant centers (accounting for 5.5% of the
worldwide ITx experience). This incidence is in stark con-
trast to the North American centers which represent more
than 75% of the global ITx activity, resulting in a highly
skewed literature reporting [7,22]. As mentioned, in
(a) (b)
Figure 3 One- and 5-year patient (Panel
a)/graft (death uncensored; Panel b)
survival rates (Kaplan–Meier analysis).
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Belgium five ITx centers (of seven Tx centers) performed 24
ITx. This is a relatively high number of centers for a small
population (11 million inhabitants), but, one should real-
ize that medical care in Belgium has not been centralized
(compared to the Netherlands and the UK). However, cur-
rently the number of active centers has reduced and at the
moment of writing, the only Belgian ITx candidates
(n = 2) were listed at one center (University Hospitals Leu-
ven). This is consistent with the ITR data which indicate
that the number of active ITx centers has reduced from 87
to 46 worldwide [7].
ITx patient characteristics in Belgium, however, are quite
different to the profile reported by the ITR, with pediatric
ITx representing only 26% of the total activity in Belgium
versus 56% in the ITR [22]. We have no clear explanation
for this discrepancy. The liver sparing lipid free/poor TPN
management and strict hygienic line policies have been
standard in Belgium for more than a decade and this may
have led to less referral for intestinal and liver transplanta-
tion. Alternatively, and particularly at the start of the pro-
gram, too late referral of moribund patients who were too
sick to undergo ITx may have played a role. Finally, pediat-
ric cadaveric organ donation in Belgium is relatively low.
Currently, children have no prioritization on the waiting
list for ITx. The only exception (for children and adults) is
the cLi-ITx or MvTx who receive prioritization over all
liver (except high-urgency) and isolated ITx candidates.
This is the so-called Eurotransplant mandatory exchange sta-
tus.
Indications for ITx on the other hand are quite similar
between Belgium and the ITR, with short bowel syndrome
due to ischemia or volvulus being the most frequent. In
contrast to cLi-ITx representing the most frequently trans-
planted type of graft in the Belgian experience (46%) versus
31% in the ITR, the isolated intestinal graft is most fre-
quently transplanted worldwide (according to the ITR,
45%) versus 37.5% in the Belgian experience. Although
MvTx has been performed less frequently (16.5% in Bel-
gium versus 23.5% according the ITR) indications such as
splanchnic thrombosis are increasing [22,25].
MvTx has become a viable lifesaving surgical option for
patients suffering from extensive porto-mesenteric throm-
bosis who remain unresponsive to medical treatment or
surgical shunt techniques [25]. However, extensive abdom-
inal surgery in these patients is challenging and frequently
complicated by major, uncontrollable bleeding, requiring
massive transfusion, with considerable morbidity, and
mortality. The four MvTx cases, reported herein, were very
similar as complete portal thrombosis—extending deeply
into all venous mesenteric branches—had caused conges-
tion of the entire small bowel in all of them, thereby
decreasing the absorptive function and making these
patients TPN dependent. MvTx was the only feasible
Figure 4 The 5-year patient survival rate of 13 consecutive intestinal
transplant recipients—who received their graft from a deceased donor
—and were treated with an immunomodulatory protocol was 90%,
which is higher compared to the other nine patients who did not receive
the protocol and had a survival of 33% (log rank, P = 0.0055) (Kaplan–
Meier analysis). In the same era (2000–2013) worldwide, 5-year patient
survival according to the International Transplant Registry was 58%.
Figure 5 Intestinal transplant (ITx) activ-
ity within Belgium (white bars) and Euro-
transplant (ET) (black bars) between 1987
and May 31, 2014.
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option and treatment that could fully restore the anatomi-
cal portal drainage of the intestine. In three cases, complete
preoperative embolization of the superior mesenteric artery
and celiac trunk safely facilitated native organ exenteration
prior to MvTx. Details of this strategy were recently
reported by the first author of this paper [14].
Interesting and particularly challenging in ITx candidates
is preoperative renal failure and the indication for simulta-
neous kidney transplantation. From the 24 ITx performed
in Belgium, 5 also received a kidney graft (21%). Three of
the Belgian patients were on dialysis, and the fourth and
fifth patient already had a severely impaired renal function
with a pretransplant eGFR of 34 and 37 ml/min, respec-
tively. We believe that inclusion of a renal allograft in case
of limited renal function pretransplant (GFR< 30–40 ml/
min) should be strongly considered. Indeed, ITx and expo-
sure to calcineurin inhibitors has a well-known negative
effect on renal function and, in turn, post-transplant renal
impairment increases the mortality rate by a factor up to 6
[26,27].
Another pitfall in ITx resides in the closure of the
abdominal wall. Previous repeated surgery and enterectomy
frequently results in a shrunken hostile abdominal domain
and decreased abdominal wall elasticity [28]. Preferentially
donors which are smaller in size should be selected. In the
Belgian experience, the donor/recipient weight ratio of 0.92
fitted within the generally recommended ratio of 0.76–1.1
[29]. The technique of pretransplant tissue expansion was
successfully applied in two patients reported herein.
Similar to the ITR data, most Belgian patients received
induction IS (Basiliximab or ATG) (83% in Belgian cohort
versus 72% in the ITR) and tacrolimus-based maintenance
IS. Overall rejection rate in the Belgian cohort was 45%, a
figure slightly lower than reported by most centers (50–
60%). This might be explained by inclusion of more than
half of the patients in an immunomodulatory protocol
described in details elsewhere and based on the administra-
tion of DSBT under low levels of IS and in a low-inflamma-
tory environment [16,17]. Indeed, the incidence of
rejection in this cohort was relatively low: 2 (15%) patients
developed early acute rejection, 3 (23%) late acute rejection
and none chronic rejection. All rejections were reversible.
Under this protocol, applied in 13 consecutive ITx from
deceased donors, only two patients (15%)—who both
received an isolated ITx—died. One to an invasive Asper-
gillosis (following antirejection therapy) at 8.5 months, the
other to an unforeseen NSAID-induced graft enteropathy
almost 12 years after ITx [30].
For this cohort of patients who received the immuno-
modulatory protocol, six received a liver-containing graft.
Therefore, one cannot exclude that the favorable outcome
could be attributed in part to the “liver-protective” effect.
However, it is known that this effect applies particularly in
the long term, is far from universal, and does not systemati-
cally override rejection.
Although gastroenterologists and general physicians have
become aware of the therapeutical and lifesaving option of
ITx for a selected number of patients, the procedure unfor-
tunately remains confronted with long waiting times and a
mortality rate on the waiting list of up to 50%. Therefore
early referral, adequate evaluation and timely activation on
the waiting list are advocated [31]. For selected patients,
and non-ET residents who have no access to the organ pool
(as in the case described herein), living-related donation
might avoid this waiting list. To our knowledge, only two
other living-related ITx were performed within ET. The
first successful living-related intestinal graft donation
worldwide was performed by Deltz in Kiel (Germany) on
August 8, 1988 [32] and the second in Frankfurt am Main
(Germany) [33]. Although living donation might offer sev-
eral advantages like: (i) planned procedure with a limited
cold ischemia time; (ii) the possibility of HLA matching;
and (iii) the ability to transplant at the optimal moment
for the recipient, experience remains limited.
Conclusion
ITx has come of age in Belgium as a life-saving treatment
in selected patients with reduced life expectancy due to IF
and significant complications from TPN. During the last
15 years, 24 ITx were performed in five centers, accounting
for 15% of the ET activity. Five-year patient and graft sur-
vival rates of 62.8% and 53.1%, respectively, were achieved,
which is similar to long-term results reported by the ITR.
All survivors were nutritionally independent and experi-
enced an improved Karnofsky performance score.
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